Robocath, which is developing robotic-assisted technology for cardiovascular diseases, has collected capital from investors including TUS-Holdings.
Robocath, a France-based developer of a cardiovascular disease treatment system developer, raised €40m ($43.4m) in a series C round yesterday backed by Luxembourg CLIIF, an investment fund managed by the Tsinghua University-affiliated TUS-Holdings,
Medical device manufacturer MicroPort Scientific led the round, which also included regional investment vehicles Go Capital, NCI and Normandie Participations, and national investment funds M Capital and Supernova Invest.
Financial services firm Crédit Agricole’s Unexo and Crédit Agricole Normandie units filled out the round with…
